Integer Holdings resets 2026 outlook as customer forecasts shift and product ramps slow

What happened

Integer Holdings has updated its 2026 outlook, citing changes in customer forecasts and slower-than-expected product ramps that will pressure growth and margin recovery, with the trajectory now dependent on adoption timing. The company had previously flagged select headwinds for 2026 in its 2025 guidance update, aiming to return to above-market organic growth in 2027. Despite solid 2025 momentum—Q2 sales up 11.4% year-over-year and a raised FY25 outlook—the reset underscores execution risks in micro-machining (Pulse) and neurovascular (InNeuroCo) programs. The DeepValue master report had already noted these risks, valuing the stock at ~30x P/E and ~58x EV/EBITDA with little cushion. The news confirms that near-term headwinds are materializing, delaying the expected inflection.

Implication

Investors should brace for potential downward revisions to 2026 estimates as the reset confirms slower ramp timelines. The premium valuation (~30x P/E) is vulnerable to multiple compression if growth disappoints further. Key watch items: execution on Pulse and InNeuroCo programs, quarterly order trends, and any signs of leverage drifting above 3.5x. A pullback to more reasonable multiples (e.g., ~25x P/E) or tangible proof of 2027 acceleration could create a buying opportunity. For now, maintain a HOLD and await a better risk/reward entry.

Thesis delta

The thesis shifts from 'watchful hold' to a more cautious stance as the 2026 reset confirms headwinds are real and potentially deeper than initially flagged. While the long-term CDMO moat remains intact, the timing of growth inflection is now less certain, raising the probability of a near-term de-rating. The prior assumption that 2026 would be a temporary hiccup is now under pressure, requiring more patience or a lower entry price.